# Type 1 vs Type 2 Diabetes (USMLE)

> What is the difference between type 1 and type 2 diabetes on USMLE?

The antibodies, C-peptide values and treatment lines that separate type 1 from type 2 diabetes, plus the insulin and antidiabetic drug tables boards test.

Type 1 diabetes is autoimmune T-cell destruction of pancreatic beta cells causing absolute insulin deficiency, while type 2 diabetes is peripheral insulin resistance with a relative, progressive insulin deficit. Type 1 requires lifelong exogenous insulin from diagnosis; type 2 starts with metformin plus lifestyle change, adding GLP-1 receptor agonists or SGLT2 inhibitors before insulin becomes necessary.

## What is the difference between type 1 and type 2 diabetes on USMLE?

**Type 1 diabetes is autoimmune, and type 2 is metabolic.** Autoreactive T cells destroy beta cells, so insulin collapses and glucagon acts unopposed: a lean child or young adult presents with polyuria, polydipsia, and weight loss, often in ketoacidosis, carrying **GAD-65, IA-2, insulin, or ZnT8** antibodies and **HLA-DR3/DR4**.

**Type 2 diabetes begins with insulin resistance, and beta cell failure follows.** Muscle and fat stop responding, the liver overproduces glucose, and beta cells compensate with hyperinsulinemia until they exhaust, so **C-peptide stays detectable** and ketosis is rare. Type 1 also clusters with [autoimmune thyroid disease](/blog/thyroid-disorders-usmle) and celiac disease; the [Endocrinology](/topics/endocrinology) hub covers the rest.

## Type 1 vs type 2 diabetes: side-by-side comparison

Seven variables separate the two diseases on a stem.

| Feature | Type 1 diabetes | Type 2 diabetes |
| --- | --- | --- |
| **Onset** | Childhood, abrupt; LADA in adults | After 40, or in obese teens; insidious |
| **Mechanism** | Autoimmune beta cell destruction -> absolute deficiency | Insulin resistance -> relative deficiency |
| **HLA and antibodies** | HLA-DR3/DR4; GAD-65, IA-2, insulin, ZnT8 positive | No HLA link; antibodies negative |
| **Acute crisis** | Diabetic ketoacidosis | Hyperosmolar hyperglycemic state |
| **C-peptide** | Low or undetectable | Normal or high early, falling late |
| **Habitus** | Lean, recent weight loss | Central obesity, acanthosis nigricans |
| **First-line treatment** | Basal-bolus insulin, lifelong | Metformin; add GLP-1 RA or SGLT2 inhibitor |

## Diagnostic criteria for diabetes mellitus

**Any one of four tests makes the diagnosis**, and an abnormal result needs repeat confirmation unless hyperglycemia is unequivocal.

| Test | Diabetes | Prediabetes |
| --- | --- | --- |
| **Fasting plasma glucose** (8-hour fast) | >=126 mg/dL | 100-125 mg/dL |
| **2-hour 75 g OGTT** | >=200 mg/dL | 140-199 mg/dL |
| **HbA1c** | >=6.5% | 5.7-6.4% |
| **Random glucose with classic symptoms** | >=200 mg/dL | -- |

HbA1c tracks red cell lifespan, so hemolysis, bleeding, and pregnancy make it **falsely low**; use fasting glucose instead.

## Insulin preparations: onset, peak, and duration

Onset and peak decide insulin questions.

| Insulin | Onset | Peak | Duration | Clinical use |
| --- | --- | --- | --- | --- |
| **Rapid-acting** (lispro, aspart, glulisine) | 5-15 min | ~1 hour | 3-5 hours | Mealtime bolus; pumps |
| **Short-acting** (regular) | ~30 min | 2-3 hours | 5-8 hours | Only IV insulin: DKA, HHS, hyperkalemia |
| **Intermediate** (NPH) | 1-2 hours | 4-10 hours | 12-18 hours | Twice-daily basal; nocturnal hypoglycemia |
| **Long-acting** (glargine, detemir, degludec) | 1-2 hours | No peak | ~24 hours | Once-daily basal; least hypoglycemia |

## Oral and non-insulin antidiabetic drugs

Six non-insulin classes cover nearly every type 2 question.

| Class | Mechanism | Key benefit | Key risk | Board pearl |
| --- | --- | --- | --- | --- |
| **Metformin** | ↑ AMPK, ↓ hepatic gluconeogenesis | No hypoglycemia; weight neutral | Lactic acidosis, B12 deficiency | Hold for contrast; avoid if eGFR <30 |
| **Sulfonylureas** (glipizide) | Close beta cell K-ATP channels | Potent, inexpensive | Hypoglycemia, weight gain | Useless in type 1 -- needs live beta cells |
| **GLP-1 agonists** (semaglutide) | Incretin mimetic; ↓ glucagon, ↓ gastric emptying | Weight loss, cardiovascular benefit | Nausea, pancreatitis | Avoid with medullary thyroid cancer/MEN2 |
| **SGLT2 inhibitors** (empagliflozin) | Block proximal tubule glucose reabsorption | Renal and heart failure benefit | Genital mycotic infection | Causes **euglycemic DKA**, classically post-op |
| **DPP-4 inhibitors** (sitagliptin) | Block endogenous GLP-1 degradation | Oral, minimal hypoglycemia | Arthralgia, pancreatitis | Weight neutral, *not* weight losing |
| **Thiazolidinediones** (pioglitazone) | PPAR-γ agonist -> ↑ insulin sensitivity | Durable, no hypoglycemia | Fluid retention, fractures | Avoid in NYHA III-IV heart failure |

Acarbose blocks intestinal disaccharidases, causing flatulence -- one of many [high-yield drug side effects](/blog/high-yield-drug-side-effects-usmle) tested.

## Diabetic complications and their mechanisms

Chronic hyperglycemia injures tissue through glycation, the polyol pathway, and protein kinase C activation.

Tissues that cannot regulate their own glucose uptake take the damage: nerve, retina, lens, and glomerulus import glucose independently of insulin, so intracellular glucose tracks the plasma level. In Schwann cells the aldose reductase step also burns the NADPH needed to regenerate glutathione, so osmotic swelling and oxidative injury compound, and the longest axons fail first.

- **Nephropathy.** Hyperglycemia dilates the afferent arteriole, causing **glomerular hyperfiltration**; glycation thickens the basement membrane, producing albuminuria, **Kimmelstiel-Wilson nodules**, then falling GFR. An **ACE inhibitor or ARB** dilates the efferent arteriole, lowering intraglomerular pressure and slowing progression.
- **Neuropathy.** Aldose reductase converts glucose to **sorbitol** using NADPH in Schwann cells, retina, and lens, which lack sorbitol dehydrogenase; osmotic injury yields **stocking-glove sensory loss**, painless ulcers, and gastroparesis.
- **Retinopathy.** Ischemia drives **VEGF**, turning nonproliferative disease (microaneurysms, dot-blot hemorrhages, exudates) into **proliferative neovascularization**; treat with anti-VEGF or panretinal photocoagulation.
- **Macrovascular disease.** Glycation end products accelerate atherosclerosis, so infarction and stroke dominate mortality; autonomic neuropathy makes the infarct **silent**, and statins are indicated regardless of LDL.

## DKA versus HHS, and the hypoglycemia algorithm

Both crises stem from insulin deficiency, but only DKA makes ketoacids.

Insulin's antilipolytic action is the hinge. When insulin falls to essentially zero in type 1 diabetes, hormone-sensitive lipase strips adipose triglyceride into free fatty acids while glucagon lowers malonyl-CoA and releases **carnitine palmitoyltransferase I**; beta oxidation then delivers acetyl-CoA faster than the citric acid cycle absorbs it, and the surplus leaves the liver as acetoacetate and beta-hydroxybutyrate. Residual insulin in type 2 diabetes is far too little to restrain hepatic glucose output but still enough to hold lipolysis down, so ketogenesis never starts and glucose instead climbs until osmotic diuresis and dehydration concentrate the serum into **HHS**.

| Feature | DKA | HHS |
| --- | --- | --- |
| **Patient** | Type 1; missed insulin or infection | Type 2, elderly, poor water access |
| **Glucose** | 250-600 mg/dL | Often >600 mg/dL |
| **Chemistry** | Anion gap acidosis, pH <7.3, ketones; Kussmaul breathing | pH >7.3, few ketones, osmolality >320; obtundation |
| **Treatment** | Fluids and potassium first, then insulin; dextrose near 200 mg/dL | Aggressive fluids first; less insulin |

Total-body potassium is depleted in both, so **hold insulin until potassium exceeds 3.3 mEq/L**, and use **anion gap closure, not glucose**, to declare DKA resolved.

> **10-second exam strategy:** Glucose under 70 mg/dL in an alert patient gets **15-20 g oral carbohydrate, recheck at 15 minutes, repeat until above 70**, then a meal; if obtunded, **IV dextrose**, or **IM glucagon** without IV access. **High C-peptide** means sulfonylurea or insulinoma; **low** means exogenous insulin.

## How this is tested on the exam

- **Lean 14-year-old, polyuria, Kussmaul breathing, glucose 480** -> type 1 DKA; fluids before insulin.
- **Obese 52-year-old, acanthosis nigricans, HbA1c 7.8%** -> type 2; start metformin.
- **Nursing home resident, glucose 940, osmolality 345, no ketones** -> HHS; isotonic fluids.

## Common wrong-answer traps

- **Trap: assuming adult onset means type 2.** A lean adult failing metformin quickly with positive GAD-65 antibodies has **LADA** and needs insulin.
- **Trap: giving insulin before fluids in DKA.** Volume and potassium come first, since insulin drives potassium intracellularly.
- **Trap: blaming metformin for hypoglycemia.** Metformin never stimulates insulin release; sulfonylureas and meglitinides do.

## Sources

- [ADA Standards of Care in Diabetes](https://professional.diabetes.org/standards-of-care)
- [NIDDK diabetes and kidney disease](https://www.niddk.nih.gov/health-information/kidney-disease)

Diabetes vignettes reward pattern recognition across antibodies, insulin kinetics, and drug side effects -- [Practice endocrinology questions on StepGenie](https://dashboard.stepgenie.app/sign-up) until these distinctions are automatic.

## Frequently asked questions

### How do you tell type 1 from type 2 diabetes on a question stem?

Type 1 diabetes shows a lean patient, usually a child or young adult, with abrupt polyuria, polydipsia and weight loss, positive GAD-65, IA-2, insulin or ZnT8 antibodies, low C-peptide, and HLA-DR3/DR4. Type 2 diabetes shows central obesity, acanthosis nigricans, an insidious course found on screening, negative antibodies, and normal or high C-peptide early in the disease.

### What are the diagnostic criteria for diabetes mellitus?

Diabetes is diagnosed by any one of four results: fasting plasma glucose of 126 mg/dL or higher after an eight-hour fast, a two-hour glucose of 200 mg/dL or higher on a 75 g oral glucose tolerance test, an HbA1c of 6.5% or higher, or a random glucose of 200 mg/dL or higher with classic hyperglycemic symptoms. Confirm abnormal results unless hyperglycemia is unequivocal.

### Which insulin is given intravenously in diabetic ketoacidosis?

Regular (short-acting) insulin is the preparation given intravenously, so it is the answer for diabetic ketoacidosis, hyperosmolar hyperglycemic state and hyperkalemia. Rapid-acting analogs such as lispro, aspart and glulisine are for mealtime bolus dosing and pumps, while NPH and the long-acting analogs glargine, detemir and degludec provide basal coverage and are never used to treat a hyperglycemic crisis.

### Why does an ACE inhibitor or ARB protect the kidney in diabetes?

Diabetic nephropathy starts with afferent arteriolar dilation and glomerular hyperfiltration, which raises intraglomerular pressure and drives basement membrane thickening, mesangial expansion and albuminuria. An ACE inhibitor or ARB dilates the efferent arteriole, lowering that intraglomerular pressure and slowing progression independently of its blood pressure effect. Expect a small early creatinine rise, which is acceptable and not a reason to stop the drug.

### What is the difference between DKA and HHS?

DKA occurs mainly in type 1 diabetes: absolute insulin deficiency permits ketogenesis, giving an anion gap acidosis with pH below 7.3, glucose usually 250 to 600 mg/dL, Kussmaul breathing and abdominal pain. HHS occurs in type 2 diabetes, where residual insulin suppresses ketones, so glucose often exceeds 600 mg/dL with serum osmolality above 320 and profound dehydration without significant acidosis.

---

Canonical page: [Type 1 vs Type 2 Diabetes (USMLE)](https://www.stepgenie.app/blog/diabetes-type-1-vs-type-2-usmle)
Topic hub: [Endocrinology](https://www.stepgenie.app/topics/endocrinology)